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Abstract
Author Manuscript

The cytoskeletal interacting protein Septin 9 (SEPT9), a member of the septin gene family, has
been proposed to have oncogenic functions. It is a known hot spot of retroviral tagging insertion
and a fusion partner of both de novo and therapy-induced mixed lineage leukemia (MLL). Of all
septins, SEPT9 holds the strongest link to cancer, especially breast cancer. Murine models of
breast cancer frequently exhibit Sept9 amplification in the form of double minute chromosomes,
and about 20% of human breast cancer display genomic amplification and protein over expression
at the SEPT9 locus. Yet, a clear mechanism by which SEPT9 elicits tumor-promoting functions is
lacking.
To obtain unbiased insights on molecular signatures of SEPT9 upregulation in breast tumors, we
overexpressed several of its isoforms in breast cancer cell lines. Global transcriptomic profiling
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supports a role of SEPT9 in invasion. Functional studies reveal that SEPT9 upregulation is
sufficient to increase degradation of the extracellular matrix, while SEPT9 downregulation inhibits
this process. The degradation pattern is peripheral and associated with focal adhesions (FA), where
it is coupled with increased expression of matrix metalloproteinases. SEPT9 overexpression
induces MMP upregulation in human tumors and in culture models and promotes MMP3 secretion
to the media at FAs. Downregulation of SEPT9 or chemical inhibition of septin filament assembly
impairs recruitment of MMP3 to FAs. Our results indicate that SEPT9 promotes upregulation and
both trafficking and secretion of MMPs near FAs, thus enhancing migration and invasion of breast
cancer cells.
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Septin 9; invasion; migration; breast cancer; focal adhesions; oncogene; metalloproteinases;
MMP3

Introduction

Author Manuscript

Septin 9 (SEPT9) is a GTP-binding protein that assembles into hetero-oligomeric complexes
in the form of filaments and rings1. At the genomic level, it is the most complex member of
the septin family of genes, coding for up to 18 isoform variants, and is, to date, the septin
with the strongest association to cancer. SEPT9 was first linked to tumorigenesis in 1999 by
the discovery of therapy induced chromosomal translocations between the SEPT9 locus and
the mixed lineage leukemia (MLL) gene in an acute myeloid leukemia (AML) patient2.
Septins are the protein family most frequently involved in rearrangements with MLL3.
MLL-SEPT9 fusions are highly heterogeneous in terms of both patients’ age (4 months–72
years), and clinical presentation (myelodysplastic syndromes as well as acute myeloid
cases), suggesting a broad implication in the tumorigenic process3. SEPT9 transcripts are
generated by splicing or coded by alternative promoters4, 5. SEPT9 isoforms include a
central common core (exons 4–11) and differing 5’ and 3’ ends3. While mechanistically the
contribution of MLL partners to the tumorigenic process remains largely unknown, it is well
established that fusion genes have oncogenic functions. This suggests that SEPT9 acts as a
bona fide oncogene.

Author Manuscript

In solid tumors, SEPT9 was originally proposed as a tumor suppressor gene as it maps to a
region of loss of heterozygosity in some breast and ovarian tumors6. However, several
reports now suggest that this is not the case. SEPT9 was identified as a hot spot of viral
integration in retroviral insertion mutagenesis experiments7, and it is amplified in murine
models of breast cancer in the form of double minute chromosomes8, both of which are
molecular properties of strong oncogenes9. Genomic amplification of SEPT9 leads to its
overexpression in human and murine breast adenocarcinomas and in a variety of breast
cancer cell lines8. The likely mechanism of SEPT9 tumorigenic activity is via upregulation
of its transcripts, given that mutations of this gene are rare in cancer10. This is supported by
mining The Cancer Genome Atlas11. Upregulation of the transcript variant SEPT9_v1 has
been reported in human cell lines as well as in matched tumor and peritumoral breast cancertissue specimens5, 12, 13. Expression of the SEPT9_v3 isoform is regulated by DNA
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methylation upstream of the SEPT9_v3 transcription start site14. Overexpression of SEPT9
is detected more commonly in high-grade carcinomas, which are also associated with a
worse clinical prognosis5.
Septins play pivotal roles in cytoskeleton dynamics; accordingly, they are linked to a broad
range of cellular functions, many of which have the potential to foster tumorigenic
phenotypes. SEPT9_v1 promotes tumor growth by stabilizing HIF-1α15, while SEPT9_v4
has been shown to increase resistance to microtubules-interacting drugs16. SEPT9_v1 is
upregulated in breast cancer and is associated with oncogenic potential via its interaction
with c-Jun12, 17.

Author Manuscript

One proposed mechanism for SEPT9 contribution to tumorigenesis is to promote tumor
metastasis via enhancing migration18. We previously performed migration assays using
MCF7 cells expressing GFP-tagged SEPT9 isoforms and showed that SEPT9_v1,
SEPT9_v3, SEPT9_v4, and SEPT9_v5 have increased numbers of migratory cells,
suggesting that SEPT9 contributes to the migratory phenotype. Analysis of morphogenesis
of renal cysts using MDCK cells grown in 3-D revealed that SEPT9 overexpression doubled
the number of cellular extensions and their length, suggesting a more aggressive tumor
phenotype due to SEPT9 upregulation19.

Author Manuscript

While it is recognized that SEPT9 contributes to tumorigenesis, a clear mechanism of action
by which SEPT9 elicits its tumor-promoting functions is lacking. To begin addressing this
significant gap of knowledge, we overexpressed three SEPT9 isoforms deregulated in breast
primary tumors into the hormone responsive luminal A subtype MCF7 cell line, therefore
mimicking the occurrence of the most common breast cancer subtype (luminal A, estrogen
and progesterone responsive), and performed global transcriptomic analysis20. Our results
uncovered a significant association of SEPT9 overexpression with differential expression
(DE) of genes expressed in vesicle membranes and in the lumen of the endoplasmic
reticulum (ER). Functional analysis of SEPT9-overexpressing breast tumor cells revealed
increased degradation of the ECM. SEPT9 overexpression promoted MMP upregulation and
a significant increase of matrix metalloproteinases secreted to the culture media. In human
breast cancer patients in whom SEPT9 expression is upregulated, MMP levels are also
significantly increased. ECM degradation pattern co-localized with vinculin and overlapped
with FAs at the cell membrane, suggesting that one of the oncogenic functions of SEPT9 is
to promote degradation of the ECM by mediating the transport of protease-containing
vesicles from the ER to the tumor microenvironment.

Results
Author Manuscript

Upregulation of SEPT9 isoforms SEPT9_v1, SEPT9_v2, and SEPT9_v3 in MCF7 cells
activates different but complementary oncogenic pathways.
To directly test the consequences of overexpression of the SEPT9 isoforms SEPT9_v1,
SEPT9_v2, and SEPT9_v3 we performed global transcriptomic profiling using our
previously characterized MCF7 clones as a model5. Fluorescence Activated Cell Sorting
(FACS) was used to remove GFP negative cells in order to achieve homogeneity of chimeric
GFP-SEPT9 protein expression across the pool of transfected lines (>98% GFP-SEPT9
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positive cells) (Supplementary Figure 1A). To identify SEPT9 isoform-specific gene
expression changes occurring as a consequence of SEPT9 isoform overexpression, we
performed global transcriptomic analysis using RNA-sequencing on MCF7_SEPT9_v1,
MCF7_SEPT9_v2, and MCF7_SEPT9_v3 and compared the transcriptional profile to
MCF7 control cells (MFC7_c) (Supplementary Table 1 and Supplementary Figure 1B–D).

Author Manuscript
Author Manuscript

Relative to MCF7_c (FDR < 0.05) we found that, globally, 459 normalized genes were
differentially expressed (DE): 184 genes were downregulated and 275 were upregulated.
Because we anticipated the differential gene expression between the SEPT9 isoforms to be
relatively small, we refrained from setting an arbitrary cut-off for fold change, allowing us to
detect all possible statistically significant changes in expression. Of the 459 genes that met
the FDR<0.05 criteria, 58 were DE between MCF7_SEPT9_v1 and MCF7_c (36
downregulated and 22 upregulated)(Figure 1A), 99 were DE between MCF7_SEPT9_v2 and
MFC7_c (34 downregulated and 65 upregulated), and 302 were DE between
MCF7_SEPT9_v3 and MCF7_c (114 downregulated and 188 upregulated). The fold
difference in log normalized expression varied between 6.072 and +9.11(Figure 1B), with
204 genes DE by 1.5 folds or more. Surprisingly, we found minimal overlap between the DE
genes identified as result of overexpression of different isoforms supporting previous reports
that SEPT9 isoforms may provide complementary but unique functions4, 5, 14, 21–24. Seven
genes were DE in all MCF7 clones, of which two were upregulated (Figure 1C and Table 1).
Among those, the TCR Gamma Alternate Reading Frame Protein (TARP) which encodes for
an alternative T-cell receptor protein, is a novel breast and prostate tumor-associated
antigen25. TARP is localized to the outer mitochondrial membrane26 and its overexpression
increase the growth rate of epithelial cells and induce caveolins expression27. RNA
(UPK1AS1), a novel uncharacterized noncoding RNA, is also expressed in the mammary
epithelium28 and in the mammary gland29.

Author Manuscript

Two genes were downregulated in all three MCF7_SEPT9 isoform clones: SEC14-Like
Lipid Binding 4 (SEC14L4), which encodes a member of Sec14-like phosphatidylinositol
transfer proteins that functions as one of the key regulators of phosphoinositide signaling of
trafficking through the trans-Golgi network30; and Shisa Family Member 2 (SHISA2),
which encodes an endoplasmic reticulum (ER) protein that cell-autonomously inhibits FGF
and Wnt signaling by preventing the maturation and the cell-surface expression of their
receptors31. Remarkably, two genes, Amphiphysin (AMPH) and Solute Carrier Family 17
Member 9 (SLC17A9), both associated with vesicle mediated transport, were both
upregulated in MCF7_SEPT9_v1 and MCF7_SEPT9_v3 but were downregulated in
MCF7_SEPT9_v2 cells. On the contrary, Sulfatase 1 (SULF1), an extracellular heparan
sulfate endosulfatase enzyme that is secreted through the Golgi, was downregulated in
MCF7_SEPT9_v1 and MCF7_SEPT9_v3 but was upregulated in MCF7_SEPT9_v2 cells.
When considered globally, all DE genes common to the three SEPT9 isoforms were
significantly enriched in genes expressed in the lipid bilayer of membranes (GO:0016020),
suggesting that membrane dynamics is an important consequence of SEPT9 over expression
in epithelial breast cancer cells.
Of the DE genes that were found common in two SEPT9 isoforms (Supplementary Figure
2A and Supplementary Table 2), three were common to MCF7_SEPT9_v1 and
Oncogene. Author manuscript; available in PMC 2020 January 08.
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MCF7_SEPT9_v2: Cadherin 4 (CDH4), Caveolin 1 (CAV1) and ATPase,
aminophospholipid transporter (APLT), class I, type 8A, member 1 (ATP8A1), suggesting
again a pivotal role of membrane bound proteins. Eighteen genes were common to
MCF7_SEPT9_v2 and MCF7_SEPT9_v3, enriched in the cellular component GO term
vesicle lumen (GO:0031983, p=1.61e-02), Aldolase C, fructose-bisphosphate (ALDOC),
Leucine-rich alpha-2-glycoprotein 1 (LRG1), and vascular endothelial growth factor C
(VEGFC)(Supplementary Figure 2B), as well as positive regulation of cell migration (GO:
0030335). Significant enrichment of the 18-gene set was also found in GO terms associated
with regulation of secretion. When overlaid with genes of the phospholipid signaling
pathway (Supplementary Figure 2B blue lines) we identified significant enrichment (p<0.05)
within genes common to MCF7_SEPT9_v2 and MCF7_ SEPT9_v3.

Author Manuscript

A total of 16 genes common to MCF7_SEPT9_v1 and MCF7_SEPT9_v3 were found to be
involved in the Protein Kinase A (PKA) signaling pathway (Supplementary Figure 2C).
Because of the limited overlap of DE genes between the SEPT9 isoforms, we proceeded to
analyze individually the transcriptome of each MCF7 clone overexpressing the different
isoforms.
At the level of single genes, the top 10 up- and downregulated MCF7_SEPT9_v1 genes
were associated with functions important for antigen binding and processing
(Supplementary Table 3). These genes are conventionally expressed in the cellular
compartment of the Golgi apparatus. The top 10 up- and downregulated genes identified in
MCF7_SEPT9_v2 and MCF7_SEPT9_v3 cells were not significantly associated, as a group,
to specific GO terms.

Author Manuscript

Globally, Gene Set Enrichment Analysis (GSA) of all significantly DE genes relative to
MCF7_c cells revealed that MCF7_SEPT9_v1-overexpressing cells were mainly expressed
in the endoplasmic reticulum and the Golgi apparatus (Figure 1D), and were enriched for
antigen processing and response to cytokine stimulus pathways (FDR= 6.02E-06), as well as
tissue remodeling and regulation of cell to cell adhesion (Supplementary Figure 3A and
Supplementary Table 4). We identified a significant association of DE genes in response to
SEPT9_v1 upregulation with hallmarks of protein secretion and apical surface markers
(Supplementary Figure 3A blue and red lines). Interestingly, we found a significant
enrichment (FDR =5.78E-03) with regulation of pinocytosis (CAV1 and the AXL Receptor
Tyrosine Kinase AXL1 gene). AXL1 is a signal transducer regulating communication of
epithelial cells with the extracellular matrix and it has been involved in several functions
including promoting cell invasion32.

Author Manuscript

MCF7_SEPT9_v2 cells were enriched for cell growth functions (FDR= 1.79E-03) and
response to growth factor stimulus (FDR= 6.77E-03) (Supplementary Figure 3B and
Supplementary Table 4). MCF7_SEPT9_v3 cells were mainly associated with vesicles
(Figure 1E) and mostly enriched in pathways controlling excretion (FDR= 2.9E-02) and
lipid localization and transport (FDR=3.3E-03). Overlay of the Biocarta TGFβ pathway
gene members with enriched GO terms as result of SEPT9_v3 overexpression revealed an
extensive overlap between these two groups (Supplementary Figure 3C and Supplementary
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Table 4). To verify the biological finding that SEPT9_v1, SEPT9_v2 and SEPT9_v3 may
promote isoform specific differential gene expression, we randomly selected six genes
(Versican -VCAN, T-Box Transcription Factor TBX15, Sulfatase 1 -SULF1, Glypican 6 GPC6, Keratin 20 -KRT20 and Fibroblast Growth Factor 21 -FGF21). These targets, which
included high and low expressing genes as well as transcripts upregulated or downregulated
in one or more isoform specific MCF7 lines, showed similar trend of expression in MCF7
cells as determined by quantitative PCR across 3 independent lines, each expressing one
SEPT9 isoform (Supplementary Figure 4).
When considered as a whole, the transcriptomic profiling analysis of MCF7 cells
overexpressing SEPT9_v1, SEPT9_v2, and SEPT9_v3 isoforms points to altered cell
communication between cells and the microenvironment via vesicle formation and
membrane dynamics.

Author Manuscript

SEPT9 overexpression promotes invasion and migration

Author Manuscript

Because the RNA-sequencing results strongly supports a role for SEPT9 in the dynamics of
vesicles and their interaction with the extracellular matrix, we reasoned that one of the
oncogenic functions linked to its overexpression in breast cancer cells is to promote
invasion. We therefore proceeded to functionally test this hypothesis in vitro. Among the
features that contribute to cell invasiveness are cell motility and their ability to degrade the
surrounding extracellular matrix (ECM). We previously showed that SEPT9 expression in
MCF7 cells contributes to the migratory phenotype of these cells (Figure 2A and14). To
verify that this effect was not restricted to MCF7 cells, we generated stable MDA-MB-231
clones, expressing GFP-tagged SEPT9 isoforms SEPT9_v1, SEPT9_v2, or SEPT9_v3. The
pro-migratory and invasive potential of each of the MDA-MB-231 clones was tested using
the transwell migration assay with collagen-coated inserts14. The ability of the cells to
migrate/invade in the transwell assay relies on their motility as well as their ability to
degrade the matrix through which they migrate. Expression of all three SEPT9 isoforms
showed, as in MCF7 cells, a significant increase in the number of migratory/invading cells
(p<0.05), suggesting that the pro-migratory and invasive effect of SEPT9 in mammary
epithelial cells is likely a general phenomenon (Figure 2A.
SEPT9 overexpression increases cellular degradation of fluorescent matrix

Author Manuscript

Among the genes enriched in SEPT9-overexpressing MCF7 cells, several were involved in
cytoskeletal organization, cell-cell adhesion, and secretion, all of which can contribute to
metastasis by promoting ECM degradation. We subsequently wanted to test whether the
expression of the SEPT9 isoforms in mammary epithelial cells affects the cells’ ability to
digest the ECM. We performed matrix degradation assays, using 2-dimensional fluorescent
analysis using MDA-MB-231 clones because of their high degrading phenotype33, 34.
Initially we tested the three different GFP-SEPT9 variants to determine to what extent they
differed in their matrix degradation activity. MDA-MB-231_SEPT9_v3 was the most
degrading SEPT9 isoform. This agrees with our RNA-Seq analysis indicating that
SEPT9_v3 overexpressing cells are enriched for the expression of genes controlling cell-cell
adhesion and excretion when compared with WT cells. Therefore, we proceeded to perform
a more detailed analysis comparing matrix degradation in MDA-MB-231_SEPT9_v3
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relative to MDA-MB-231_c cells. In order to estimate the degradation potential of the cells,
we quantified gelatin degradation by calculating the total degradation area for each panel of
images as percentage of total cells’ area (Supplementary Figure 5A). This approach provides
a normalized and highly reproducible way to compare control cells to SEPT9 overexpressing
cells. We found that SEPT9_v3 overexpression significantly increases the gelatin
degradation activity of MDA-MB-231 cells of about 2.5 folds (4.69±0.69% vs. 1.92±0.53%,
respectively; P<0.033, Figure 2B–C). These results suggest that, in addition to contributing
to migration, SEPT9_v3 overexpression in MB-MDA-231 cells also promotes matrix
degradation under these experimental conditions.
SEPT9 knockdown decreases cellular degradation of fluorescent matrix

Author Manuscript

To confirm that the effect of gelatin degradation was indeed a function of SEPT9 activity in
MDA-MB-231 cells, we tested the consequence of SEPT9 downregulation on gelatin
degradation. To this end, MDA-MB-231_c cells were transfected with siRNA targeting
SEPT9 or with a scramble siRNA (control). Cells were analyzed 48 hours post-SEPT9
silencing to ensure decreased levels of SEPT9 mRNA as well as SEPT9 protein (82%
mRNA reduction relative to scramble siRNA treated cells - Supplementary Figure 6A; and
75% protein expression decrease -Supplementary Figure 6B–C). The SEPT9 silenced and
control cells were next tested for their ability to degrade fluorescent gelatin. The results
revealed that reduction of ~80% of SEPT9 mRNA levels relative to controls leads to
significantly lower degradation activity compared with that of cells treated with control
siRNA (1.94±0.15% vs. 5.77±0.39%, respectively; P<0.001; Figure 2D–E and
Supplementary Figure 5B). These results support the hypothesis that SEPT9 is required for
extracellular matrix degradation in breast cancer cells.

Author Manuscript

SEPT9 overexpression promotes secretion of proteases into the cell media

Author Manuscript

As suggested by our global transcriptomic results, SEPT9 may promote ECM degradation
through enhanced secretion of matrix metalloproteinases (MMPs) to the media. In fact,
MCF7 cells overexpressing SEPT9_v3 are enriched in excretion pathways, and significantly
over express genes associated with MMPs activity (Supplementary Figure 7). Consequently,
to examine if SEPT9_v3 overexpression affects the levels of proteases secreted to the media
we used a protease array to analyzed the cell culture medium for the presence of 34 different
proteases (Supplementary Figure 6E–F). To maximize the potential difference in secreted
proteases, we compared the conditioned medium of MDA-MB-231 cells transfected with the
SEPT9 siRNA to the conditioned medium of MDA-MB-231 cells expressing SEPT9_v3
(Supplementary Figure 6B–D). We found that the levels of two secreted proteases, Matrix
Metalloproteinase MMP3 and MMP13, were significantly decreased in the culture medium
of MDA-MB-231 cells transfected with SEPT9 siRNA (~40%) (Figure 3A–B). These results
indicate that SEPT9 promotes secretion of MMPs to the media. Interestingly, there was no
change in the secreted MMP2 and MMP9 levels, the metalloproteinases implicated in
invadopodia-mediated matrix degradation35, 36.
To better understand the correlation between SEPT9 and MMPs, we wanted to establish if
SEPT9 overexpression directly promoted MMPs expression and also evaluate the generality
of this process by analyzing multiple breast cancer cell lines. We designed primers for the
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quantitative measurement of mRNA coded by an array of MMPs: MMP3 and MMP13 were
selected based on the protein array results (Figure 3A–B), and MMP1, MMP2, and MMP9
are widely studied matrix-degrading enzymes enriched at invadopodia35, 37–42. The levels of
these five degrading enzymes were quantified by qRT-PCR in MCF7, MDA-MB-231, and
T47D either overexpressing SEPT9_v3 or not overexpressing SEPT9_v3. MMP13
expression was significantly upregulated as a consequence of SEPT9_v3 overexpression in
all three cell lines tested (Figure 3C). MMP1 was significantly upregulated in both MCF7
and MDA-MB-231, the latter of which also upregulated MMP3. The mRNA of MMP2 and
MMP9, in concordance with the protease array results (Figure 3C), was expressed at low
levels in MDA-MB-231 as well as the other cell lines tested and therefore we could not
detect significant changes (data not shown).

Author Manuscript

Because SEPT9 is amplified in ~20% of breast cancer cases43 and because MMPs are key
regulators of the mammary tumor microenvironment that mediate ECM degradation and
remodeling44, we mined The Cancer Genome Atlas (TCGA) to study a possible correlation
between SEPT9 and MMPs in human sporadic breast cancer. Of the n=1093 cases analyzed
as part of the provisional breast cancer dataset, ~19% (n=210) express SEPT9 at 1.5 folds
higher than the median levels across all cases. In these samples, from the global
transcriptomic profiling, MMP levels were detected across all 210 cases for 8 out of the 23
known MMPs (MMP1, MMP9, MMP11, MMP14, MMP15, MMP19, MMP24, MMP25).
We found that 4 out of these 8 MMPs (MMP9, MMP15, MMP24 and MP25) were
significantly upregulated in those patients that also overexpressed SEPT9 (Figure 3D), while
no significant expression changes were detected in the other MMPs.

Author Manuscript

Thus, SEPT9 overexpression directly promoted MMPs upregulation in cultured cells, and
human tumors with high SEPT9 expression also significantly upregulating the expression of
several MMPs.

Author Manuscript

Involvement of MMP secretion with extracellular vesicles (EVs) activity is an emerging
field45, 46; we next wanted to test whether SEPT9 affects EV secretion. We isolated EVs
from conditioned medium of MDA-MB-231 overexpressing SEPT9_v3 and MDA-MB-231
transfected with control RNAi or SEPT9 RNAi. The isolated EVs were analyzed by
dynamic light scattering47, as well as laser scattering microscopy48, 49. Both analyses failed
to detect significant differences in secreted EV numbers or size (Supplemental Table 5). This
implied that SEPT9 affects either the EV cargo, or the MMP’s secretion pathway by directly
enhancing exocytosis into the medium and/or activation of MMP activity during secretion.
To distinguish among these mechanisms, we separated the EVs from the MDA-MB-231
culture media to obtain EV-free media. To ensure EV depletion we tested for the presence of
CD9, a marker for EVs50, which was present in whole cell lysate and in the EV fraction but
not in the conditioned medium (Figure 4A). MMP3 expression was detected in the whole
cells extract and in the supernatant fraction but not in the EV-free conditioned medium. This
supports the hypothesis that MMP3 is secreted directly to the medium and not via EVs and
SEPT9 affects this activation and/or secretion. Moreover, while the protein size of MMP3
expressed in the cells was the expected 57kDa size, MDA-MB-231 cells expressing
SEPT9_v3 contained a truncated form. MMP3, like other MMPs, contains a pro-peptide of
~80 amino acids51, which is cleaved upon secretion resulting in a smaller but active MMP3
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form (45 kDa, MMP3’). When comparing the supernatant fraction of MDA-MB-231_c and
MDA-MB-231_SEPT9_v3 cells, the latter secreted higher levels of MMP3’ (4.78+/− 0.07
folds increase) (Figure 4B), strengthening the notion that SEPT9 promotes secretion of
protease activated MMPs to the media.
SEPT9 is associated with Focal Adhesions degradation sites and MMP3

Author Manuscript

We next sought to further characterize the relation between SEPT9 activity and extracellular
matrix degradation in MDA-MB-231 cells. The degradation pattern exhibited by MDAMB-231 is peripheral (Figure 2B) and resembles the pattern of focal adhesion (FA) ECM
degradation52. To determine whether FAs drive the observed degradation pattern and
whether SEPT9 is associated with these structures, we stained MDA-MB-231 cells grown on
gelatin with pan-SEPT9 and the FA marker vinculin. As expected, SEPT9 assembled into
filaments that partially colocalize with F-actin. However, this localization was uneven along
the F-actin filaments, as previously described for SEPT2 and other septins53 (Figure 5A–B).
We also found that SEPT9 localized adjacent to FAs, which appeared to extend from the
SEPT9 and F-actin filaments (Figure 5A, white arrow). These findings are in accordance
with previous studies showing that SEPT9 directly cross-links prepolymerized actin
filaments into bundles and promotes maturation of nascent FAs19. Moreover, the vinculin
staining patterns were very similar to the gelatin degradation patterns (Figure 5C), implying
that the ECM degradation observed under these conditions is associated with FAs.

Author Manuscript

In addition to the interaction with F-actin and the association with FAs, SEPT9 has been
shown to interact with microtubules8, 19, 54–56. Moreover, studies indicate that septins
participate in Golgi-to-plasma membrane vesicle transport57, 58 suggesting that SEPT9 may
be involved in trafficking of MMPs from the Golgi to mature FAs. Hence, we examined the
association between SEPT9, FAs, F-actin, and MMP3. First, MDA-MB-231 cells were
seeded on gelatin and stained for F-actin, vinculin, and MMP3. Interestingly, the MMP3
signal appeared as a tubular staining, which in some instances localized along F-actin
filaments. The MMP3 tubular staining extended from the cell center towards the cell edge,
and specifically towards FA, where MMP3 is expressed in foci (Figure 5D, arrows).

Author Manuscript

Next, we asked whether SEPT9 depletion affects either FAs, as previously demonstrated19,
or the tubular morphology of the MMP3 staining. To address this, MDA-MB-231 cells
transfected with siRNA targeting SEPT9 or with a scramble siRNA (control), were seeded
on gelatin before staining with F-actin, vinculin, and MMP3 and analyzed for FA
morphology and number. Notably, SEPT9 depletion decreased the number of mature FAs
and had some effect on the MMP3 signal (Figure 6; Supplementary Figure 8). Image
analysis revealed that cells transfected with SEPT9 siRNA had significantly shorter FAs
(Figure 6B; SEPT9, 1.1±0.26 μm; CONT, 1.3±0.2 μm; p<0.02) than control cells. Moreover,
SEPT9 depletion significantly decreased the number of FAs larger than 472 nm (2 pixels)
(Figure 6C; SEPT9, 48±6.2; CONT, 80±9.7; p<0.01), while increasing the percentage of
FAs localizing distal to the cell edge relative to control cells (Figure 6D). These results
demonstrate that SEPT9 depletion affects the maturation of FAs, which is characterized by
both elongated FAs and FA position closer to the cell center19. However, the effect of SEPT9
depletion on MMP3 was not as striking (Supplementary Figure 9). While the size
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distribution of the MMP3 signals was affected slightly (Figure 6E; SEPT9, 59% of the
signals were shorter than 944 nm and 41% longer; CONT, 29 % of the signals were shorter
than 944 nm and 71% longer, P<0.01), the average signal distribution of the MMP3 signals
was similar between control and SEPT9 siRNA cells (Figure 6F). This could be partly due to
cell-to-cell variability of SEPT9 silencing using siRNA, as well as limitations in the ability
of SEPT9 siRNA to equally target all the 18 known SEPT9 isoforms that assemble the septin
complex resulting in residual filament assembly12, 59. To test whether a more severe
phenotype on MMP3 secretion could be observed using a septin inhibitor, we exposed
MDA-MB-231 cells to forchlorfenuron (FCF). FCF impairs septin dynamics and
mammalian septin organization, and it has been shown to inhibit exocytosis of secreted
proteins in various cells55, 60. If our hypothesis is correct, stabilization of septin filaments
which impairs their dynamics should severely affect the maturation of FAs and destroy the
tubular pattern of MMP3 expression. MDA-MB-231 cells were seeded on gelatin and
incubated with 50 μM FCF or DMSO control followed by staining for F-actin, vinculin, and
MMP3. As predicted (Figure 7A), FCF impaired the formation of mature FAs as well as the
tubular expression of MMP3. FCF-treated cells had statistically significant smaller and
fewer central FAs than DMSO-treated cells, indicating that FCF inhibits the maturation of
the FAs (Supplementary Figure 10). Likewise, the tubular appearance of MMP3 was
impaired by FCF and most of the FCF-treated cells showed a main centrally located MMP3
signal with only few distal foci (Supplementary Figure 11). Quantification of the images
revealed that DMSO-treated control MDA-MB-231 cells had significantly longer FAs
(Figure 7B; DMSO, 1.3±0.1 μm; FCF, 1.1±0 μm, P<0.001) than FCF-treated cells.
Additionally, FCF treatment, like SEPT9 depletion, significantly decreased the number of
FAs larger than 472 nm (2 pixels) (Fig. 7C; DMSO, 142±13.5; FCF, 109±11.8, P<0.1),
while increasing the percentage of distal FAs near the cell edge relative to control cells (Fig.
7D). Like SEPT9 depletion, FCF altered the size distribution of the MMP3 signals, as we
predicted (Figure 7E; FCF, 68% of the signals were shorter than 944 nm −4 pixels- and 32%
were longer; DMSO, 45% of the signals were shorter than 944 nm and 56% were longer,
P<0.01). In addition, FCF significantly shortened the average length of the MMP3 signals
(Figure 7F; DMSO, 1.3±0.07 μm; FCF, 1.1±0 μm, P<0.001).
Collectively, these results support the hypothesis that SEPT9 promotes invasiveness by
increasing the maturation of FAs and facilitating MMP3 trafficking and secretion at FAs.

Discussion
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The main goal of this work was to study the consequences of SEPT9 overexpression in
breast cancer cells. Given the strong association between SEPT9 amplification and
overexpression in breast cancer5, 8, 14, 61 and the previously reported SEPT9 functions in
enhancing migration14, 19, we reasoned that this protein would function as a bona fide
oncogene, granting cells tumor-promoting characteristics. The transcriptomic profiling of
MCF7 cells overexpressing three of the major SEPT9 isoforms found in mammary epithelial
cells clearly indicate that SEPT9 promotes invasion. Altogether, the enrichment analysis on
gene sets differentially expressed in MCF7-overexpressing SEPT9 isoforms points to
regulation of cell motility, cell-cell adhesion, lipid metabolism, vesicle transport and
secretion.
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Some of these properties have been previously linked to septins, while others were a novel
discovery of our study. Epithelial-Mesenchymal Transition (EMT) requires epithelial cells to
gain migratory and invasive potential. It has been previously shown that septins promote
motility of renal epithelial cells19. Here we demonstrate that the enhanced motility is also
maintained in mammary epithelial cells. We previously demonstrated, using a transwell
migration assay, the pro-migratory effect of SEPT9 expression on the low-migratory MCF7
cells. Here we show that even highly motile and invasive MDA-MB-231 cells further
increase this phenotype when SEPT9 is overexpressed. Thus, SEPT9 strongly contributes to
migration. This conclusion is consistent with previous in vivo studies showing that
SEPT9_v1 stabilizes HIF-1α15 and that the HIF-1a signaling pathway is directly associated
with invasive tumor cell migration in breast tumors62.
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The greatest effect on migration was achieved by expression of SEPT9_v1, both in MCF7
and MDA-MB-231 cells. This further supports the growing concept that SEPT9 isoforms
contribute differently to tumorigenesis. It was recently proposed that SEPT9_v2 acts as an
inhibitor of migration in MCF7 cells and that this specific isoform is downregulated in
primary breast tumors13. The weak tumorigenic potential of SEPT9_v2 is supported by our
transcriptomic analysis of MCF7 cells overexpressing this isoform when compared to
SEPT9_v1 or SEPT9_v3. In fact, we found DE genes as consequence of SEPT9_v2
overexpression to be the least enriched in molecular, cellular, and biological functions
compared to the other two isoforms tested.
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The major outcome of the transcriptomic profiling analysis was the enrichment of tissue
remodeling and cell adhesion pathways along with the novel findings linking SEPT9
overexpression in mammary epithelial cells to excretion. Notably, genes differentially
expressed as consequence of SEPT9 overexpression were significantly associated with
cellular component ontologies related to the plasma membrane, especially the lumen side of
the endoplasmic reticulum and membrane vesicles. This is in concordance with recent
findings based on proteomic analysis63. Septins can bind to membranes, specifically to
phosphoinositides (PIs)64, where they provide membrane stability and serve as diffusion
barriers for membrane proteins65, 66. While some mechanisms linking SEPT9 functions to
phospholipids and vesicle transports in mammalian cells are emerging67, 68, most of our
knowledge remains restricted to yeast biology. However, it is important to note that the
phosphoinosities are essential regulatory scaffolds linking invadopodium precursor
formation to the proximal tip of FAs69, which is consistent with the results of our study
linking SEPT9 to the emergence of proteolysis at FAs.

Author Manuscript

One of the features of invasion is the ability of cells to degrade their surrounding matrix.
Here we provide evidence that SEPT9_v3 overexpression in MDA-MB-231 cells increases
their ability to degrade gelatin, whereas global knockdown of SEPT9 in the same cells
decreases their degradation potential. These results suggest that increased levels of SEPT9 in
mammary epithelial cells promotes degradation of the extracellular matrix, providing a
functional link between SEPT9 amplification and overexpression and its oncogenic
properties. The most profound effect on degradation was demonstrated by expression of
SEPT9_v3 which, when expressed in MCF7 cells, was accountable for enrichment in genes
involved in secretion. The different effect of the SEPT9 isoform variants on migration vs.
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degradation implies that SEPT9 isoforms may be accountable for complementary but unique
functions.
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Degradation activity of the ECM is a key feature of invadopodia, which is achieved by the
secretion of proteases that degrade the basement membrane surrounding the tumor70. The
characteristic pattern of gelatin degradation by cancer cells is a centrally situated and dotshaped degradation pattern that localizes with invadopodia69–72. However, the degradation
pattern exhibited by MDA-MB-231 cells in our study was mostly peripheral and localized at
the basal membrane that bridges the actin cytoskeleton to the ECM, and the pattern
resembled ECM degradation by FAs. This type of proteolytic degradation mechanism has
been previously described both in fibroblasts and in epithelial cells73 and shown to be
associated with invadopodium precursor assembly at the proximal tips of FAs in breast
cancer cells69. In fact, we show here that in MDA-MB-231 cells SEPT9 localizes in adjacent
to FAs and that the degradation patterns formed by these cells are similar to the FA staining
patterns. FAs are integrin-containing, multi-protein structures that form mechanical
connections between intracellular actin bundles and the ECM. The dynamic assembly and
disassembly of FAs plays a central role in cell migration. In order to allow movement, FAs
have to release and disassemble at the ventral side of the cell body. It was suggested that FA
disassembly is facilitated by FA-targeted, local exocytosis leading to ECM degradation,
causing disassembly of integrin-matrix connections. Microtubules anchored near FAs serve
as tracks for transport of EVs and deliver MT1-MMP to the cell surface membrane, which
can activate MMPs and degrade the extracellular matrix around FAs, resulting in integrin
detachment, loss of tension, and FA turnover52, 74. Dolat and colleagues previously showed
that septin filaments expressed at the leading edge of motile renal epithelia cells promote
cell motility by reinforcing the organization of the lamellar stress fiber network and the
stability of nascent FAs. Furthermore, this septin function was shown to rely on the ability of
SEPT9 to directly cross-link preassembled F-actin filaments, promoting the maturation of
nascent FAs19. The direct binding of SEPT9 to F-actin was demonstrated by electron
microscopy and it was suggested that SEPT9 could maintain the integrity of growing and
contracting actin filaments75. Septins are also implicated in microtubule-dependent
transport, which involves the regulation of microtubule motor interactions with cargo.
Intriguingly, it has been shown that SEPT9 interacts with a microtubule motor (KIF17) and
it was proposed that SEPT9 may act as a regulator of cargo-motor binding by either
affecting the loading of cargo to KIF17 or triggering the release of cargo from KIF1776. It is
possible that in addition to promoting FA stabilization, SEPT9 functions as a mediator of
MMP trafficking, activation, and secretion, thereby promoting ECM degradation.
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Our transcriptomic analysis of MCF7 cells overexpressing SEPT9_v3 uncovered a
significant enrichment in genes involved in MMP secretion. Here, we functionally show that
SEPT9 expression directly results in MMPs upregulation in several breast cancer cell lines,
and that SEPT9 upregulation promotes secretion of MMP3 and MMP13 to the cell media in
MDA-MB-231. We also provide evidence that the link between SEPT9 upregulation and
MMPs activity is maintained in human breast cancer. Secreted MMPs play a crucial role in
cellular invasion through modulation of cell–cell and cell–ECM interactions77, 78. Most
secreted MMPs require activation post-secretion by cell surface MMPs such as MT1-MMP,
which is known to mediate ECM degradation at FAs73; some of these secreted MMPs, such
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as MMP2 and MMP9, which are activated by MT1-MMP, are involved in direct degradation
of the ECM. However, other MMPs can bind to their respective membrane receptors after
their activation and initiate signal transduction pathways that influence the cell’s migration
and invasion. MMP3 (stromelysin-1) is a known inducer of epithelial–mesenchymal
transition (EMT) that has been shown to promote mammary carcinogenesis79–81. It is also
involved in the activation process of MMP9, consequently promoting breast tumor
progression82, 83. Interestingly, MMP3 is also required for branching morphogenesis in the
mammary gland84–86 and has been shown to be markedly upregulated during pregnancy and
involution of the mammary gland87, 88. MMP13 (Collagenase 3) is known to be efficiently
activated by MT1-MMP89. Its expression is associated with advanced local invasion in
human squamous cell carcinomas of the larynx90, and it was suggested to play a potentially
significant role in breast cancer invasion and metastasis91. It is intriguing to speculate that
SEPT9 promotes cell invasion at least partly by enhancing the levels of the secreted MMP3
and MMP13. Because SEPT9 acts in concert with other members of the septin family92, and
septins other than SEPT9 have been found expressed in FA19, it is likely that SEPT9 acts in
concert with other septin filaments that, as a whole, provide a structural network and/or
docking sites for MMPs and other proteolytic enzymes at FAs, contributing to extracellular
matrix degradation. Indeed, FCF is not SEPT9 specific, but stabilizes higher-order assembly
of the septin family as a whole. While FCF off targets effects have been reported in
mammalian cells93, it is possible that they are an indirect consequence of alteration of
septins dynamics given the larger number of organelles and functions they partake. Further
research is needed to clarify whether or not SEPT9, and other septins, also affects the
transport of MT1-MMP to FAs and to elucidate the mechanism by which it promotes MMP
secretion at FA sites. Elucidating the role of SEPT9 in matrix metalloproteinases dynamics
is significant since these proteins are required for the initial metastatic steps and have been
proposed as pharmacological targets for anti-metastatic therapy94, 95.
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Collectively, previous studies linking SEPT9, FAs, and microtubules, together with the data
presented here, imply that the interaction of SEPT9 with the cytoskeleton promotes both
trafficking and secretion of MMPs near FAs, thus enhancing migration and invasion of
breast cancer epithelial cells. In our model, tumor cells without SEPT9 overexpression
(Figure 8A) (i.e. lower than 1.5-fold the mean expression as suggested by the results shown
in Figure 3D) degrade the ECM mainly through mature ventral invadopodia projections
which have been shown to function as regulatory structures for the secretion of MMP2 and
MMP935, 37–42. SEPT9 overexpression in cancer cells (Figure 8B) promotes the assembly of
a septin network that includes SEPT9 and likely other septin members, which promotes the
delivery of MMP3, MMP13, and possibly other proteases to the plasma membrane at FAs.
As a result, ECM degradation is highly enhanced at FAs. The molecular mechanisms by
which this process is regulated, the key proteins responsible for the delivery of proteases to
FAs, and whether proteolytic enzymes and MMPs other than MMP3 and MMP13 are
involved in this process remain to be elucidated.
Protease secretion at invadopodia is regulated by cortactin, which was proposed to link
vesicular trafficking and dynamic branched actin assembly37. Phosphorylation of cortactin
was shown to lead to activation of the actin binding protein, cofilin, which induces F-actin
polymerization in the invadopodium core and consequently MMP recruitment70, 96. F-actin
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polymerization at FAs is directly driven by SEPT919, which was shown to bind F-actin at
sites that overlap with regions involved in the binding of cofilin75. It is noteworthy that
invadopodia assemble at the proximal tip of FAs69, and the later maturation of invadopodia
involves transition of FA proteins to invadopodia97–99. We therefore propose that SEPT9mediated actin polymerization and phosphoinositol mobilization at nascent FAs enhances
the formation of invadopodium precursor assembly leading to MMP secretion and activation
at FAs. Thus, FAs serve as sites for enhanced vesicular trafficking, protease secretion, and
ECM degradation in SEPT9 overexpressing cells.

Materials and Methods
Cell lines
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MCF7 clones overexpressing GFP chimera SEPT9_v1, SEPT9_v2, and SEPT9_v3 isoforms
were previously described14. MDA-MB-231 and T47D cells (DTP/DCTD/NCI Tumor
Repository) expressing the same GFP-fused SEPT9 isoform constructs were generated using
the approach previously described for MCF7 cells5. All cell lines were maintained at low,
post-G418 selection passage, and cultured only for up to one month; all lines were grown in
low-glucose DMEM supplemented with 8% fetal bovine serum and incubated in 5%
CO2/37°C. FACS for the removal of GFP negative cells was performed using live MCF7
clones. About 5×106 cells were trypsinized, washed in 2ml of 0.5%BSA in PBS, resuspended in 0.5ml of 0.5%BSA in PBS, and then filtered using a 40μm cell strainer (Falcon
Corning, Corning NY). GFP negative cells were used as a control and to set the threshold of
positive intensities. FACS was performed using the BD FACSAria II (BD Biosciences, San
Jose, CA) equipped with a 100μm nozzle and a pressure of 20psi at 4°C. Cells were sorted in
5ml of complete media and immediately plated overnight to allow recovery.
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RNA isolation and cDNA synthesis
Low passage MCF7_SEPT9_v1, MCF7_SEPT9_v2, and MCF7_SEPT9_v3-overexpressing
cell lines and the MCF7 control cells (MCF7_c) were placed in culture simultaneously and
split to establish three biological replicates; the plates were taken from culture when they
reached 70% confluence. The cells were then lysed directly on the plate with Qiazol lysis
reagent (Qiagen, Valencia, CA) and placed at −80°C until all samples were ready for RNA
extraction. Total RNA was isolated using the miRNeasy kit (Qiagen, Valencia, CA) and
assessed using an Agilent Bioanalyzer. All RNA had an RNA integrity number (RIN) score
of 10.
Library Preparation and RNA-sequencing
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A total of 12 samples were used for RNA-Seq analysis (three biological replicates from each
of the MCF-7 isoforms and control cells). Sequencing libraries for the Illumina 2500
platform were created from the polyadenylated fraction of RNA from each cell line. mRNA
was then isolated with Dyna1 oligo-dT beads (Invitrogen, Carlsbad CA) from 10μg of total
RNA. The mRNA was randomly fragmented using the RNA fragmentation kit from
Ambion. First-strand cDNA synthesis was performed using random primers and
SuperScriptII reverse-transcriptase (Invitrogen, Carlsbad CA). This was followed by secondstrand cDNA synthesis using DNA Polymerase I and RNase H (Invitrogen, Carlsbad CA).
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The Illumina adaptor was ligated to the ends of the double-stranded cDNA fragments and a
200bp size-selection of the final product was performed by gel-excision, following the
Illumina-recommended protocol. Template molecules of 200bp cDNA with the adaptor
attached were enriched by PCR to create the final library. Libraries were pooled and
sequenced in two lanes on the Illumina HiSeq (2500) Sequencing System (Illumina, San
Diego, CA) using 150bp reads at the New York Genome Center (New York, NY). Sequences
in fastq format as well as normalized data files have been deposited into Gene Expression
Omnibus (GEO)100 (Project ID# GSE119449 entitled: ”Septin 9 over expression in MCF7”).
RNA-sequencing analysis and identification of candidate genes
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We generated a total of 4.3×107 reads, an average of ~36 million reads per library
(Supplementary Table 1 and Supplementary Figure 1B), of which 92.3–93.8% could be
uniquely mapped to the NCBI Build37/hg19 of the human reference genome. To rule out 3’
bias of poly A+ libraries, we plotted the coverage across the gene body (5’ -> 3’) in all cell
lines analyzed by RNA-Seq. We determined that the highest percentage of reads was
observed between the 25th and 85th percentile of the gene bodies, therefore excluding bias
towards the 5’ end of the mRNA sequences and thus excluding technical confounding
factors (Supplementary Figure 1C). On average 88.38% of the reads mapped to coding
sequences (CDS) (87–90%) (Supplementary Figure 1D). We found, across all samples
analyzed, that 16,743 genes had five or more reads corresponding to 80.93% of the MCF7
genome being transcribed.
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Pass filter sequences were aligned to the NCBI Build 37hg19 reference genome. Alignments
were then referenced against an annotation database that combines ENSEMBL (release 71),
GENBANK/NCBI (release 196), and REFSEQ (release 60). All statistical methods, and data
analysis were conducted using the R statistical software101. For QC of sequencing results we
used the RSeQC package102, uniquely aligned sequences were analyzed using the DESeq
package, and to illustrate the expression differences for each gene and to plot the average of
the normalized counts per million (CPM) across biological replicates and the standard error
for each condition, we used the ggplot2 package103. Heatmaps were created using the
heatmap.3 function in the GMD package104.
For all analyses, a P-value <0.05 was considered significant and all P-values were adjusted
for multiple testing using Benjamini-Hochberg correction where a cutoff FDR value <0.1
was considered significant.
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Gene ontology was determined using g:profiler including, as a background, all genes across
the three MCF7 clones with >5 reads and FDR<0.5, adjusted for multiple testing using the
Benjamini & Hochberg method. Enrichment maps were visualized using The Enrichment
Map Cytoscape Plugin. Gene sets comprising hallmarks of apical surface (M5916),
hallmarks of protein secretion (M5910), EGD1 signature (Phospholipids as signaling
intermediaries, M10579), and members of the TGFβ pathway (M18933) were obtained from
the Molecular Signatures Database (MSigDB)105. Pathway analysis was performed using the
web interphase Reactome.org106.
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For silencing of SEPT9, we used the siRNA SMARTpool (Dharmacon Cat #L-006373,
Lafayette USA). ON-TARGET SEPT9 oligos were used for gene specific downregulation
and same MCF7 or MDA-MB-231 cells transfected with the ON-TARGET Non-targeting
(scramble) siRNA Control Pools were used as a reference. siRNA pools were resuspended
using manufacturer procedures in RNase-free 1x siRNA Buffer at a final concentration of 20
mM. Cells were transfected using DharmaFECT Transfection Reagent according to
manufacturer’s instructions. After transfections, cells were allowed to grow for 48 hours
before analysis of specific endpoints.
Real-Time qRT-PCR
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Total RNA was isolated from cells as reported previously8. cDNA was reverse-transcribed
from 5μg of total RNA using random primers and SuperScript II Reverse Transcriptase
(Invitrogen). Primer3 software107 was used to design SEPT9 primers (F- 5’CCCCAGAAGGAATTTGATGA −3’; R- 5’- TGGTACCCCACTTGGTCTTC −3’) along
with glyceraldehyde 3-phosphate dehydrogenase (GAPDH) primers (F- 5’CCACATCGCTCAGACACCAT-3’; R- 5’-CCAGGCGCCCAATACG-3’). Primers for
MMP1, MMP2, MMP3, MMP9, and MMP13 were selected from KiCqStart Primers
(MilliporeSigma, Burlington, MA) by choosing those mapping to exons spanning all known
isoforms for each gene: H_MMP1_2, H_MMP2_3, H_MMP3_2, H_MMP9_3,
H_MMP13_2. H_GAPDH_1 was also obtained from Sigma and tested together with the
custom-designed GAPDH primers described above. Due to the low expression levels of
MMP2 and MMP9, a TaqMan assay was also performed for these two genes using MMP2 Hs00234422_m1, MMP9 - Hs00234579_m1, GAPDH - Hs99999905_m1 (Roche
LifeScience) as we previously described8. Predesigned TaqMan probes and primers for
VCAN (Hs00171642_m1), TBX15 (Hs00537087_m1), SULF1 (Hs00290918_m1), GPC6
(Hs00170677_m1), KRT20 (Hs00300643_m1), FGF21 (Hs00173927_m1) and GAPDH
(Hs99999905_m1) were obtained from ThermoFisher.
Real-Time qRT-PCR was performed using Applied Biosystems Fast SYBR Green Master
Mix and TaqMan Fast Advanced Master Mix with the StepOnePlus Real-Time PCR System
(Life Technologies Corp., Carlsbad, CA, USA). Correlation analyses were performed by
computing the normalized read counts for each analyzed MCF7 line with the levels obtained
by TaqMan assay. The Pearson correlation coefficient (r) and the p value were determined in
each case.
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The Cancer Genome Atlas (TCGA) mining and statistical analysis of MMP expression in
SEPT9 overexpressing human breast cancer samples
We mined the provisional dataset of TCGA using the cBIOportal interface108 to download
the normalized expression level of SEPT9 and all known MMPs. MMP2, MMP9, MMP11,
MMP14, MMP15, MMP19, MMP24, and MMP25 had expression data which were detected
in all 1093 breast cancer patients for whom global transcriptomic profiling was available;
these expression data were therefore used for further analysis. Next, the cases were assigned
to group A or group B based on SEPT9 mRNA expression level. Group A included cases
(n=210) in which SEPT9 expression level was 1.5 standard deviations higher than the mean
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based on the z-Score (RNA Seq V2 RSEM) compared to the expression distribution of
SEPT9 in tumors that are diploid for this gene; group B (n=883) included all the remaining
cases. Group A and group B were compared for the expression of the MMPs listed above by
multiple testing analysis (ANOVA).
Western Blotting
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Cell lysates were prepared by washing cells in cold PBS followed by addition of SDS-PAGE
sample buffer containing Protease Inhibitor Cocktail (SIGMA Cat#P2714–1BTL). Cells
were transferred to a 1.5ml tube, sonicated, and heated at 95°C for 5 min. Proteins were
separated by electrophoresis in NuPAGE 10% Bis-Tris gels and transferred to PVDF
membranes (Milipore- Immobilon, FL, Cat #IPFL00010- pore size: 0.45μm) by
electroblotting. Membranes were blocked in PBS+ 5% milk powder and incubated with
primary antibodies and anti-SEPT9 rabbit antibody (Proteintech Cat#10769–1-AP) and αTUBULIN mouse antibody (Sigma Cat #T9026) overnight at 4°C. The other antibodies used
were MMP3 rabbit antibody (Arigo Biolaboratories Cat#ARG55262), CD9 mouse antibody
(Proteintech Cat#60232–1-Ig), or Actin mouse antibody (Proteintech Cat#66009–1-Ig).
After three washes in PBS-T, membranes were incubated with secondary antibodies (Mouse
680 and Rabbit 800 [LI-COR Biosciences]) for one hour at room temperature, washed three
times in PBS-T, and scanned using a high-sensitivity Odyssey Infrared Imaging System (LiCOR Biosciences). α-TUBULIN was used as a loading control. ImageJ was used for
quantification of bands intensities.
Migration assay and colony size assessment
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Transwell inserts (8μM; Millipore, Billerica, MA, USA) were coated with 25μg/mL type I
rat tail collagen (BD Biosciences Franklin Lakes, NJ, USA). Cells (5 × 104 in DMEM 0.3%
BSA) were added in triplicate for each sample to the transwell inserts and allowed to
migrate for 10 hours at 37°C. Nonmigratory cells were removed and filters were fixed in
3.7% formaldehyde/PBS for 15 minutes and stained with 0.2% crystal violet dye for 10
minutes. Migrated cells were counted and averaged from 10 fields of view per filter at 20 ×
magnification using an Axio Observer.A1 inverted microscope (Carl Zeiss MicroImaging,
Inc.). Two independent biological replicate assays were analyzed.
Gelatin coating and degradation assay
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The ability of MDA-MB-231 cells to degrade gelatin was assessed by plating cells onto
fluorescently-labeled gelatin. Gelatin MatTek dishes were prepared as described
previously109. Briefly, acid-washed MatTek dishes were coated with 50μg/ml poly-L-lysine
followed by 0.2% gelatin labeled with either Alexa Fluor 405 dye (Life Technologies, Cat
#A30000) or with Oregon Green® 488 (Molecular probes, Cat #G-13186) and sequentially
treated with 0.5% glutaraldehyde for 15 minutes at room temperature and then with 5mg/ml
NaBH4. Cells (2×105) were seeded in complete medium and allowed to attach and degrade
for 4–6 hours at 37°C in 5% CO2. Cells were then fixed with 200μl of 4% PFA for 15
minutes, permeabilized with 0.1% Triton-X for 10 minutes, and counterstained with Alexa
Fluor® 647 Phalloidin (ThermoFisher Scientific Cat #A22287).
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Fixed cells were imaged in 1x PBS at room temperature. Images were acquired on a
DeltaVision Core Microscope (Applied Precision, Issaquah, WA) using a CoolSnap HQ2
camera (Photometrics, Tucson, AZ), 60X/numerical aperture (NA) 1.4 oil objective,
standard four-channel filter set, and softWoRx software. Custom ImageJ macros were used
for the following image processing: to split and save the individual channels of the
DeltaVision .dv files as .tif files; to find and save the best focus slice from the individual zstacks; and to correct the uneven focus in the degradation channel. Because the number of
cells in each field varied and because MDA-MB-231 cells tend to move, three panels of 5×4
fields (each field 110×110 μm2) were imaged for each clone. Matrix degradation activity
was measured by the local loss of gelatin fluorescence. Gelatin degradation areas (μm2) were
measured as the total area covered by degradation holes/field in thresholded images using
the Analyze Particles tool in Fiji (National Institutes of Health, Bethesda, MD), and cell area
(μm2) was measured as the area covered by cells/field in thresholded images. For each panel,
total gelatin degradation area (sum of degradation areas in all 20 fields) was normalized by
total cell area (sum of cell areas in all 20 fields) to give degradation area as % of cell area.
Immunofluorescence microscopy
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Cells were seeded on MatTek dishes coated with 0.2% gelatin and then fixed and
permeabilized as described above. Fixed cells were counterstained with Alexa Fluor® 647
Phalloidin (ThermoFisher Scientific Cat#A22287) or with Alexa Fluor® 633 Phalloidin
(ThermoFisher Scientific Cat #A22284), for TIRF microscopy. Antibodies used for
immunofluorescence were: anti-VINCULIN (Sigma Cat# V9131) 1:400, anti-SEPT9
(Proteintech Cat#10769–1-AP) 1:200, and anti-MMP3 (Arigo Biolaboratories
Cat#ARG55262) 1:200. All Alexa Fluor secondary antibodies were from Molecular Probes
(Life Technologies, Carlsbad, CA). All primary and secondary antibodies were diluted in
blocking buffer (1% goat serum + 1% BSA in PBS). Cells were imaged on a DeltaVision
Core Microscope (Applied Precision, Issaquah, WA) using a CoolSnap HQ2 camera
(Photometrics, Tucson, AZ), 60X/numerical aperture (NA) 1.4 oil objective, standard fourchannel filter set, and softWoRx software.
Focal adhesions and MMP3 analysis
Images (tif) were used for analysis of FAs and the MMP3 signal. FAs were analyzed from
the vinculin images, and MMP3 signal from the MMP3 images, using the Focal Adhesion
Analysis server (http://faas.bme.unc.edu/) [Berginski ME, Gomez SM. (2013) The Focal
Adhesion Analysis Server: a web tool for analyzing focal adhesion dynamics [v1; ref status:
indexed, http://f1000r.es/yc] F1000Research 2013, 2:68 (doi: 10.3410/f1000research.
2-68.v1)]. Phalloidin images were used as reference for the cell boundaries.
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Protease Array assay
Secreted protease profiling was performed with Human Proteome Profiler Protease Array
from R & D Systems (Minneapolis, Minnesota, Cat#ARY021B), according to the
manufacturer’s instructions. To generate conditioned cell culture medium for the protease
arrays, 4×105 MDA-MB-231_SEPT9_v3 (overexpressing SEPT9_v3) cells and MDAMB-231 cells transfected with SEPT9 siRNA, were seeded in 60 cm plates (4×105 cells) and
grown in 3ml DMEM supplemented with 8% FBS. After 24 hours the media was changed to
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DMEM supplemented with 0.5% FBS and cells continued to grow for an additional 24
hours. The conditioned media was collected, filtered through a 22μm syringe filter unit
(Millex-GP), and kept at −80°C until use. The protease array membranes were incubated for
one hour in Assay Buffer 6. One mL of conditioned medium was combined with 500μL of
Buffer 6 and 15μL of Detection Antibody Cocktail and incubated for one hour. Assay Buffer
6 was aspirated from the wells containing the membranes. The prepared sample/antibody
mixtures were added to the membranes and incubated overnight. Membranes were then
washed with 1× Wash Buffer 3 times and incubated with diluted streptavidin-HRP for 30
minutes. Membranes were washed and treated with Chemi Reagent Mix for 1 minute. The
chemiluminescent signals of proteases were measured with a LI-COR Odyssey Fc scanner.
ImageJ was used to determine the intensities of the signals. Background levels were
subtracted from the protease signal levels and the signals were normalized by the intensities
of the reference signals in each blot.
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Isolation of Exosomes from cell culture medium
To generate conditioned cell culture medium, 2.5×105 cells were seeded on 10cm plates
coated with 0.2% gelatin and grown in 10ml DMEM supplemented with 10% FBS. After 24
hours cells were washed and media changed to DMEM supplemented with 0.5% exosomefree fetal bovine serum (prepared by centrifugation at 120,000 × g for 24 hours). Cells
continued to grow for an additional 72 hours. The conditioned media was collected and cells
were counted for normalization.
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For EV Analysis: Normalized volumes of conditioned media (~6ml) were centrifuged at
2000 × g for 20 minutes to eliminate cells, and apoptotic bodies. The supernatants were then
mixed with 3ml of Total Exosome Isolation Reagent (ThermoFisher Scientific #4478359)
and mixed well by vortexing. The mixtures were incubated at 4°C overnight and then
centrifuged at 10,000 × g for one hour at 4°C. The exosomes were resuspended in 1ml of 1x
PBS and were analyzed by laser scattering microscopy or by dynamic light scattering48, 49.
For Western Blot analysis: Cell lysates were prepared for WB as described above.
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Normalized volumes of conditioned media (~20ml) were centrifuged at 2,000 × g for 20
minutes to eliminate cells, and apoptotic bodies. The supernatants were then centrifuged at
100,000 × g for 70 min at 4°C. Next, supernatants were concentrated ~80 times using
Millipore Amicon Ultra-4 30k (Cat #UFC803024) and pellets, which contain the EVs, were
resuspended in 50μl of RIPA buffer (made from 10x SIGMA #20–188) containing Protease
Inhibitor Cocktail (SIGMA #P2714–1BTL). SDS-PAGE sample buffer was added to the
samples and they were heated at 95°C for 5 min.

Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1: MCF7 clones overexpressing isoforms MCF7_SEPT9_v1, MCF7_SEPT9_v2, and
MCF7_SEPT9_v3 differentially express isoform-specific genes.
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A. Plot of number of DE genes in MCF7-SEPT9-overexpressing isoforms relative to MCF7
control cells. Y-axis: number of DE genes; grey bars depict genes downregulated relative to
MCF7_c; black bars depict genes upregulated relative to MCF7_c. B. Fold change of DE
genes relative to MCF7_c. Each dot corresponds to a single gene. Values on the Y-axis are
expressed as log ratio of normalized fold change of differential expression when compared
to MCF7_c. C. Venn diagram depicting the overlap of DE genes between the three SEPT9
isoforms analyzed. D-E. Pie charts depicting the cellular component significantly enriched
in DE genes. D. MCF7_SEPT9_v1. E. MCF7_SEPT9_v3. Cellular components are
indicated as percentage over the whole components identified for each specific MCF7
overexpressing clone.
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Figure 2: SEPT9 promotes fluorescent matrix degradation by MDA-MB-231 cells.
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A. Transwell migration assay comparing MCF7 and MDA-MB-231 clones, each expressing
a different GFP-SEPT9 isoform fusion construct. Cells were added to transwell inserts and
allowed to migrate for 10 hours at 37°C, after which migrated cells were counted. Plotting
reflects the average number of migrated cells from two biological replicate assays conducted
for each isoform. Statistical differences were calculated using ANOVA, *p<0.05 **p<0.02.
B. Degradation patterns of MDA-MB-231_c (control) and MDA-MB-231_SEPT9_v3 cells.
Images of matrix channel are shown together with the degradation mask and the F-actin
staining (red) together with the outlines of cell areas. Bar = 50μm. C. Bar plot depicting the
percentage of gelatin degradation area (representative 4×5 panel use for analysis is shown in
Supplementary Figure 4A). Bars represent the mean of the degradation area as % of total
cell area and error bars represent the standard error of the mean (SEM). *, p < 0.033. Data
was confirmed at least by three independent experiments. D-E. Degradation patterns of
MDA-MB-231 transfected with SEPT9 siRNA or scramble (control) siRNA. Images of
matrix channel are shown with the degradation mask and the F-actin staining (red) together
with the outlines of cell areas (E). Bar = 50μm Bar plot depicting the percentage of gelatin
degradation area (representative 4×5 panel use for analysis is shown in Supplementary
Figure 4A). Bars represent the mean of the degradation area as % of total cell area and error
bars represent the standard error of the mean (SEM).
*, p < 0.001. Data was confirmed at least by three independent experiments.
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Figure 3: SEPT9 overexpression induces MMP upregulation and promotes secretion of proteases
into the cell media.
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A. Representative images of protease arrays incubated with cell culture supernatants from
MDA-MB-231_SEPT9_v3 cells (Top) and MDA-MB-231 cells transfected with SEPT9
siRNA (Bottom). B. Quantification of MMP3 and MMP13 signals that were most
suppressed in conditioned media from MDA-MB-231 transfected with SEPT9 siRNA (**
p<0.005) is shown in A. Error bars indicate SEM. Abbreviations: MMP3 - matrix
metalloproteinase-3 (Stromelysin-1); MMP13 - matrix metalloproteinase-13 (Collagenase
3). C. Bar graphs depicting the quantification of MMP1, MMP3 and MMP13 in MCF7,
MDA-MB-231 and T47D cells over expressing GFP-SEPT9_v3 relative their parental
control lines (* p<0.005; ** p<0.001) are shown. Error bars indicate SEM. D. Violin plots
depicting the expression levels of MMP9, MMP15, MMP24, and MMP25 in TCGA breast
cancer provisional cases expressing SEPT9 mRNA 1.5 folds higher than the mean (n=210)
or 1.5 folds lower than the mean (n=883).
(**** p<0.0001; *** p<0.0003; ** p<0.0035).
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Figure 4: SEPT9 overexpression promotes secretion of the active form of MMP3 into the cell
media.

A. WB analysis of Cells (C), EV fraction (EVs), and supernatant fraction (S) of conditioned
medium from MDA-MB-231 cells. MMP3 is secreted from the cells directly to the medium
but not in EVs. Size of MMP3 is ~54 kDa and size of secreted MMP3’ is ~45kDa. The CD9
was used as a marker for EVs. B. WB analysis of Cells (C), EVs fraction (EVs), and
supernatant fraction (S) of conditioned medium from MDA-MB-231_c and MDAMB-231_v3 cells. The CD9 signal in the secreted EV fraction was used as a reference for
the quantification of the levels of the secreted MMP3’.
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Figure 5: SEPT9 localizes to Focal Adhesions, gelatin degradation sites, and MMP3.
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A-B. Representative images depicting F-actin (red), SEPT9 (yellow), and vinculin (green)
staining of MDA-MB-231 cells. SEPT9 filaments partly colocalize with F-actin filaments
(arrow points at FAs extending from SEPT9 filaments). Lower panels in A show enlarged
views of the white-boxed regions. C. Representative images depicting matrix (grey), SEPT9
(red), and vinculin (green) staining. Matrix degradation pattern colocalizes with vinculin.
MDA-MB-231 cells were seeded on Alexa Fluor 405–labeled gelatin. D. Representative
images depicting filamentous MMP3 signals associated with F-actin filaments emerging
from the cell center towards focal adhesions (vinculin staining, green). Arrows point at
MMP3 foci localized at sites of FAs. Lower panels show enlarged views of the white-boxed
region. Bar=10μm. Cells were seeded on non-fluorescent gelatin.

Oncogene. Author manuscript; available in PMC 2020 January 08.

Marcus et al.

Page 31

Author Manuscript
Author Manuscript
Figure 6: SEPT9 promotes FA stabilization and MMP3 trafficking.
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A. Representative images of MDA-MB-231 cells transfected with SEPT9 siRNA or
scramble (control) siRNA grown on gelatin; F-actin (red), vinculin (green), and MMP3
(cyan). Also shown are highlighted images depicting FA highlights (FAs in yellow and cell
outlines in red) and MMP3 highlights (MMP3 in yellow and cell outlines in red). Bar=20
μm. B-C. Bar graphs depicting the quantification of FA server analysis for FAs in MDAMB-231 cells transfected with control siRNA (n= 18 cells, 1480 FAs) or SEPT9 siRNA (n=
30 cells, 1940 FAs). See corresponding FA highlights in supplementary Figure 7. B. Bar
graph indicating the FA average length (μM). C. Bar graph indicating FA number per cell.
D. Histogram of the distribution of the FAs according to their distance from the cell edge
(μM). E-F. Bar graphs indicating the quantification of MMP3 signals in MDA-MB-231 cells
transfected with control siRNA (n= 20 cells, 1922 MMP3 signals) or SEPT9 siRNA (n= 30
cells, 1669 FAs). See corresponding MMP3 highlights in supplementary Figure 8. E.
Histogram indicating the distribution of the MMP3 signals according to their length (μm). F.
Graph indicates the MMP3 signal average length (μm). We detected no significant difference
between transfected with control or SEPT9 siRNA. Error bars indicate SEM.
*, p<0.1; **, p < 0.05; ***, p < 0.01.
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Figure 7: Inhibition of Septins by FCF results in impairment of FAs and MMP3 trafficking.
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A. Representative images of MDA-MB-231 control cells (DMSO) or FCF treated; F-actin
(red), vinculin (green), and MMP3 (cyan). Also shown are FA highlights (FAs in yellow and
cell outlines in red) and MMP3 highlights (MMP3 in yellow and cell outlines in red). Bar =
20μm. B–C. Bar graphs indicating the quantification of FAs in MDA-MB-231 cells (n= 15
cells) treated with DMSO (n= 2523 FAs) and FCF (n=1307 FAs). See corresponding FA
highlights in supplementary Figure 9. B. Bar graph indicating FA average length (μm). C.
Bar graph indicating the number of FAs per cell. D. Histogram indicating the distribution of
the FAs according to their distance from the edge of the cell (μm). E-F. Bar graphs
indicating the quantification of MMP3 signals in MDA-MB-231 cells (n= 15 cells) treated
with DMSO (n=1510 MMP3 signals) and FCF (n=853 MMP3 signals). See corresponding
MMP3 highlights in supplementary Figure 10. E. Histogram indicating the distribution of
MMP3 signals according to their length (μm). F. Bar graph indicating the MMP3 signal
average length (μm). Error bars indicate SEM.
*, P<0.5; **, P < 0.1; ***, P < 0.01.
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Figure 8: General model of functional consequences of SEPT9 overexpression in breast cancer
cells.
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A. In the absence of SEPT9 upregulation, degradation of the ECM in cancer cells occurs at
invadopodia (protrusions that assemble at the ventral side of cells). After synthesis, MMPs mainly MMP2 and MMP9 (open mouth blue circles) - are directed to the endoplasmic
reticulum (ER, light blue structure at the top of the cell) and after Golgi processing (pink
large vesicular structures), MMPs are delivered to the plasma membrane primarily via
exosome secretion. B. In SEPT9-overexpressing cells, septin filaments (red = SEPT9 and
gray = other septins) assemble into a network directed to FAs. The septin network promotes
the delivery of MMP3 and MMP13 (open mouth yellow circles) to FAs, which represents
the main ECM degradation pathway in these cells. The mechanisms by which SEPT9 and
possibly other septins promote MMP3 and MMP13 secretion at FAs remains to be
elucidated (red question mark). Likewise, whether SEPT9 promotes the secretion of MMPs
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or ECM-degrading enzymes other than MMP3 and MMP13 at FAs requires further
investigation.
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Common DE genes in MCF7_SEPT9 clones
Gene

MCF7_SEPT9_v1

MCF7_SEPT9_v2

MCF7_SEPT9_v3

AMPH

1.710

−2.502

3.554

SEC14L4

−4.751

−4.262

−3.601

SHISA2

−0.973

−1.295

−0.822

SULF1

−1.246

1.386

−1.067

SLC17A9

−4.262

2.205

−1.313

TARP

1.616

1.528

3.461

UPK1A-AS1

3.809

3.554

4.135

Values are expressed as folds of DE relative to MCF7_c
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